INEM UMR7355

What INEM UMR7355 does

INEM (Immunologie et Neurogénétique Expérimentales et Moléculaires, UMR 7355) is a French public research laboratory jointly operated by the CNRS (Centre National de la Recherche Scientifique) and the University of Orléans, headquartered on the CNRS campus in Orléans and operational since 2012. The lab's research focus is the intersection of immunology and neurogenetics, with primary emphasis on exposome-driven inflammation — how environmental pollutants, allergens, and medications trigger lung inflammation, pulmonary fibrosis, allergic asthma, and neuroinflammation. It is organized into a Team 1 covering exposome and immune responses (subgroups on allergies, infection, stress, immunity; and injury-induced lung inflammation) and a Team 2 covering environmental pollutant neurotoxicity and neuroinflammation.

Underlying technology spans preclinical disease models in rodents for lung inflammation, fibrosis, and asthma; mechanistic studies of STING, NLRP3/NLRP6 inflammasomes, and gasdermin D pathways; microbiota-host-pathogen interaction work; multi-omics platforms; and organoid culture systems (including gut-lung axis models). INEM holds a portfolio of six patent families covering periostin antibodies for inflammation and fibrosis, compositions for Fragile X syndrome, synthetic phosphatidyl-myo-inositol mannoside analogues, uric-acid-reducing compounds for lung inflammation, and TNF/IL-12 overexpression compositions, and operates under ISO 9001:2015 certification.

The unit does not commercialize products and is funded through institutional allocations from CNRS and the University of Orléans, competitive grants (ANR, Region Centre Val de Loire), and European structural funds (FEDER Exposome & Inflammation project, 2021–2024). Go-to-market is community-led: outreach occurs via peer-reviewed publications, scientific seminars, conferences, public science events (Brain Week, Science Festival), and a structured international collaboration program. Its principal 'customer' segments are the academic research community (primary), pharmaceutical and biotechnology companies (preclinical efficacy testing), and public health authorities (exposome risk assessment), with technology transfer to industry via the ARTINEM joint laboratory and direct partnerships. The lab operates an international joint structure, IMHEA (IRL2029), jointly managed with the University of São Paulo since 2024 — the first International Research Laboratory in biological sciences in the Americas.

Name

INEM UMR7355

Legal name

INEM - Immunologie et Neurogénétique Expérimentales et Moléculaires (UMR7355)

Website

https://inem.cnrs.fr

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

INEM UMR7355 is a CNRS-University of Orléans public research laboratory in France studying how environmental exposures drive lung inflammation, pulmonary fibrosis, and neuroinflammation, serving academic researchers, pharmaceutical partners, and public health authorities via preclinical models, multi-omics, and international collaborations.

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

akta.pro secondary industry

Occupational Exposure Laboratory Services (Analytical Testing & Chain-of-Custody) (EUAHAGAL)

Keywords

• Immunology research
• Neuroinflammation research
• Exposome research
• Preclinical disease models
• Lung inflammation studies

Headquarters

HQ city

Orléans

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Institutional Public Funding (CNRS/University): INEM operates as a public research unit funded by CNRS and University of Orléans, receiving recurrent government funding for research operations.
2. Competitive Research Grants: The lab receives targeted research grants from regional (Region Centre Val de Loire), national (ANR), and European (FEDER, European Union) funding agencies for specific research projects.
3. Technology Transfer and Licensing: The lab develops and holds patents for therapeutic targets and compounds, with potential for licensing revenue to pharmaceutical companies.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

INEM (Immunologie et Neurogénétique Expérimentales et Moléculaires) UMR7355 is a public research laboratory jointly operated by CNRS and the University of Orléans. It conducts fundamental and translational research on inflammation, neuroinflammation, and the effects of environmental exposures (exposome) on human health, focusing on lung diseases, allergic asthma, pulmonary fibrosis, and neurotoxicity. The lab offers collaborative preclinical research services to pharmaceutical and academic partners, develops patents on therapeutic targets, and trains doctoral researchers.

Product overview

INEM (Immunologie et Neurogénétique Expérimentales et Moléculaires) UMR7355 is a research laboratory operated jointly by CNRS and the University of Orléans, France. It is not a product company and does not offer commercial products or services. The laboratory conducts fundamental research in immunology, neurogenetics, and neuroinflammation, with a focus on exposome research, environmental pollutant effects, lung inflammation, and neurotoxicity. Research activities include patent development, publications, doctoral training, and collaborative international projects.

Differentiator

Problem solved

Functional benefit

Brands

• IMHEA: International Research Laboratory (IRL2029) focused on Regulation of host responses and immune health, jointly managed by CNRS and University of Sao Paulo
• ARTINEM

Products and services

• Preclinical Research Services Validated preclinical models for lung inflammation, pulmonary fibrosis, allergic asthma, and neuroinflammation research; offered to pharmaceutical and biotechnology companies for drug candidate evaluation, preclinical efficacy testing, and mechanism of action studies.
• Collaborative Research Programs Joint research projects with academic and industry partners covering exposome effects, lung inflammation, allergic responses, and neuroinflammation; including multi-omics platforms, organoid culture systems, and access to specialized models.

Quantifiable outcome

• Publication of high-impact research with impact factors ranging from 6.4 to 18.2

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• IMHEA (IRL2029) - University of Sao PaulocoreStrategic or Co-development Partner · 1 January 2024International Research Laboratory (IRL) co-managed by CNRS and University of Sao Paulo, focusing on regulation of host responses and immune health. This is the first IRL in biological sciences in America and the second in the world. Director: José Carlos Alves-Filho (USP), Deputy Director: Nicolas Riteau (INEM).
• CNRScoreOthersCentre National de la Recherche Scientifique - the primary institutional parent organization providing core funding, administrative framework, and research infrastructure for INEM.
• Université d'OrléanscoreOthersUniversity of Orléans - co-founding institution of UMR7355, providing teaching personnel, academic programs, and research facilities.
• CRID (Centre for Research in Inflammatory Disease)coreStrategic or Co-development PartnerResearch center at University of Sao Paulo (Ribeirão Preto) focused on inflammatory diseases, key partner in IMHEA collaboration.
• CEPR (Centre d'Etude des Politiques Publiques et de la Recherche)minorOthersResearch collaboration on public policy and economic research, one of the listed institutional partners.
• Pasteur InstituteminorStrategic or Co-development PartnerPrestigious international research institute listed as partner, collaborating on scientific research initiatives.
• Macquarie UniversityminorStrategic or Co-development PartnerInternational academic partner from Australia listed among lab partnerships for research collaboration.
• PRIMMOminorOthersRegional research partner organization listed among institutional collaborators.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Helmholtz Centre for Infection Research: Large German public research center with inflammation, infection, and immunology programs that overlap with INEM's IMMUNO team. Comparable as a public-sector immunology research institution operating at significantly larger scale.
• INSERM: The French National Institute of Health and Medical Research is the dominant public health-research organization in France and operates immunology, inflammation, and respiratory research programs at a national scale. It is a natural incumbent peer against which INEM competes for talent, grants, and translational impact.
• AstraZeneca (Respiratory & Immunology R&D): Global pharmaceutical company with a major Respiratory & Immunology therapeutic area that targets asthma, COPD, and pulmonary fibrosis — exactly INEM's primary disease focus. Represents the dominant industry counterpart for any licensing or partnership deals.
• Sanofi (Inflammation & Immunology R&D): French-headquartered global pharmaceutical company with inflammation and immunology programs. Natural industry counterpart for French public-lab collaborations and a historically important partner in the French life-sciences ecosystem.
• GSK (Respiratory R&D): Pharmaceutical company with a leading respiratory portfolio (asthma, COPD) and active inflammation research. Directly relevant as the most likely large-pharma partner for INEM's respiratory inflammation IP.

Direct peers

• Institut Pasteur: France's premier immunology and infectious-disease research institute. Listed as an INEM partner and shares the immunology/microbiota/inflammation research mission with substantially broader scale and longer history, making it the closest direct peer in the French public-research landscape.
• Max Planck Institute for Immunobiology and Epigenetics: German basic-research institute focused on immune-system mechanisms and inflammation. Shares INEM's model of fundamental immunology research with multi-omics methodology and is a direct scientific peer in mechanism-driven immunology research.
• CRID (Centre for Research in Inflammatory Disease): University of Sao Paulo research center focused on inflammatory diseases and INEM's primary IMHEA partner at USP/Ribeirão Preto. Operates adjacent inflammatory-disease research programs with similar mechanistic/translational orientation, making it the most directly comparable scientific peer.
• IRSET (Institut de Recherche en Santé, Environnement et Travail): French public research institute dedicated to environmental and occupational health. Highly comparable to INEM's exposome and environmental-pollutant research focus, and represents the closest national peer for exposome-driven health research.

Others

• Charles River Laboratories: Major preclinical research-services provider whose business model of supplying validated preclinical models and efficacy testing to pharma overlaps with the translational services INEM provides through its preclinical disease-model platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/inem-cnrs

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about INEM UMR7355